期刊
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY
卷 133, 期 4, 页码 390-397出版社
AMER MEDICAL ASSOC
DOI: 10.1001/archotol.133.4.390
关键词
-
资金
- NIDCD NIH HHS [R01 DC006253-01] Funding Source: Medline
Objective: To assess the therapeutic benefit of gabapentin (Neurontin) for subjective idiopathic troublesome tinnitus. Design: An 8-week, double-blind, randomized clinical trial. Setting: Academic otolaryngology clinic in St Louis, Mo. Subjects: One hundred thirty-five subjects with severe idiopathic subjective tinnitus of 6 months' duration or longer. Intervention: Gabapentin, at a maintenance dosage of 900 to 3600 mg/d for 8 weeks, or lactose placebo. Main Outcome Measure: Change in the Tinnitus Handicap inventory score from baseline to the study end point. Results: The overall change in the Tinnitus Handicap inventory score for the entire cohort from baseline to week 8 was 11.2; the change among the 59 subjects randomized to the gabapentin arm was 11.3 and the change among the 56 subjects in the placebo arm was 11.0. The difference was 0.03 (95% confidence interval, -5.5 to 6.2; P=.91). Conclusion: Gabapentin is no more effective than placebo for the relief of idiopathic subjective tinnitus.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据